Ferritarg™ is Alissa Pharma’s lead product. Ferritarg™ is a proprietary radioimmunotherapy with an anti-ferritin antibody. It is linked to radio-isotopes to address unmet medical needs in oncology and hematology. Ferritarg™ targets cancer cells which express the ferritin antigen on the surface of the tumor cells. Overexpression of the ferritin antigen exists in Hodgkin lymphoma, pancreatic cancer, hepatocellular carcinoma (primary liver cancer) and neuroblastoma. Preclinical studies of Ferritarg™ confirmed the specificity of anti-ferritin antibody for ferritin-expressing tumors in cell culture. Ferritarg™ has been extensively tested in humans in Hodgkin lymphoma and its efficacy and safety has been demonstrated in more than 250 patients. FDA has indicated that no further preclinical data is needed before initiating a phase 2b clinical trial.
Beta emitting Yttrium(90) isotope for tumor cell destruction
Gamma emitting Indium(111) isotope for diagnostic mapping
Copyright © 2022 Alissa Pharma - All Rights Reserved.